"Hemophilia A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
| Descriptor ID |
D006467
|
| MeSH Number(s) |
C15.378.100.100.500 C15.378.100.141.500 C15.378.463.500 C16.320.099.500
|
| Concept/Terms |
Hemophilia A- Hemophilia A
- Hemophilia As
- Hemophilia, Classic
- Hemophilia
- Hemophilia A, Congenital
- Congenital Hemophilia A
- Congenital Hemophilia As
- Hemophilia As, Congenital
- Classic Hemophilia
- Classic Hemophilias
- Hemophilias, Classic
- Haemophilia
Autosomal Hemophilia A- Autosomal Hemophilia A
- As, Autosomal Hemophilia
- Autosomal Hemophilia As
- Hemophilia A, Autosomal
- Hemophilia As, Autosomal
Factor VIII Deficiency- Factor VIII Deficiency
- Factor 8 Deficiency, Congenital
- Factor VIII Deficiency, Congenital
- Deficiency, Factor VIII
|
Below are MeSH descriptors whose meaning is more general than "Hemophilia A".
Below are MeSH descriptors whose meaning is more specific than "Hemophilia A".
This graph shows the total number of publications written about "Hemophilia A" by people in this website by year, and whether "Hemophilia A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hemophilia A" by people in Profiles.
-
A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions. Pharmacoeconomics. 2025 Jul; 43(7):765-778.
-
Association Between Leg Muscle Thickness and Walking Test With the Hemophilia-Specific Functional Parameters. Am J Phys Med Rehabil. 2024 Nov 01; 103(11):986-993.
-
Emicizumab use in infancy: A survey of United States Pediatric Hemophilia Treatment Center Medical Directors. Haemophilia. 2024 May; 30(3):848-851.
-
Increasing optimal coagulation factor dosing in the paediatric emergency department: Update to a quality improvement study. Haemophilia. 2024 Mar; 30(2):367-374.
-
Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. Haemophilia. 2023 Mar; 29(2):488-497.
-
Emicizumab in pediatric hemophilia: Bleeding and surgical outcomes from a single-center retrospective study. Pediatr Blood Cancer. 2021 11; 68(11):e29325.
-
Use of ultrasound for assessment of musculoskeletal disease in persons with haemophilia: Results of an International Prophylaxis Study Group global survey. Haemophilia. 2020 Jul; 26(4):685-693.
-
Novel treatment of combined factor V and factor VIII deficiency with Factor Eight Inhibitor Bypass Activity. Haemophilia. 2020 Jan; 26(1):e21-e22.
-
Life-Threatening Tongue and Retropharyngeal Hemorrhage in a Patient with Hemophilia A with Inhibitors. Am J Case Rep. 2019 Jul 15; 20:1022-1026.
-
Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017 08 30; 117(9):1705-1713.